Is Sotac Pharma. overvalued or undervalued?

Oct 08 2025 08:04 AM IST
share
Share Via
As of October 7, 2025, Sotac Pharma is fairly valued with a PE ratio of 26.26, an EV to EBITDA of 19.97, and a PEG ratio of 0.33, making it attractive compared to peers like Sun Pharma and Divi's Lab, despite a 13.16% decline over the past year.
As of 7 October 2025, the valuation grade for Sotac Pharma has moved from very attractive to attractive. The company is currently fairly valued. Key ratios include a PE ratio of 26.26, an EV to EBITDA of 19.97, and a PEG ratio of 0.33, indicating a relatively low growth expectation compared to its earnings.

In comparison to its peers, Sotac Pharma's PE ratio is lower than Sun Pharma's 34.6 and Divi's Lab's 70.24, which are considered expensive. However, it is higher than Cipla's attractive PE of 22.68 and Dr. Reddy's Labs at 18.37, both of which suggest a more favorable valuation. Despite a recent stock return of 5% over the past week compared to the Sensex's 2.02%, the longer-term performance shows a decline of 13.16% over the past year, reinforcing the notion that the stock is currently fairly valued within its sector.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News